戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 rylation on its activator T loop in vitro by Aurora A.
2 otein ALADIN is a novel spatial regulator of Aurora A.
3  in part by a kinase-independent function of Aurora A.
4  activation, independently of the effects of Aurora A.
5 latter defect was also rescued by inhibiting Aurora A.
6  inhibition of another 49 kinases, including Aurora A.
7 a DFG conformation change at the ATP site of Aurora A.
8  is significantly reduced upon inhibition of Aurora A.
9 veloped to target specific subpopulations of Aurora A.
10 activation towards its centrosomal substrate Aurora A.
11 D pathogenesis involving failure to activate Aurora-A.
12 ance and ERalpha is a bona fide substrate of Aurora-A.
13 kdown of USP2a reduced the protein levels of Aurora-A.
14 c progression by regulating the stability of Aurora-A.
15  role of USP2a in mediating the stability of Aurora-A.
16 on impairs activating autophosphorylation of Aurora A, a cell-cycle kinase critical for meiotic trans
17 scale compartments that recruit and activate Aurora A, a critical kinase for spindle assembly.
18 rt the discovery of a selective inhibitor of Aurora A, a key regulator of cell division and potential
19                Here we report the effects of Aurora A ablation on embryo patterning at early post-imp
20                              Addition of the Aurora A activating protein TPX2 shifts the equilibrium
21  reveal a potential mechanistic link between Aurora A activation and changes in the intracellular red
22  the Aurora A activation loop is crucial for Aurora A activation by autophosphorylation.
23 that a conserved cysteine residue within the Aurora A activation loop is crucial for Aurora A activat
24 arrests cells in early mitosis by decreasing aurora A activation.
25 in, indicating an MT-dependent regulation of Aurora A activation.
26 alysis, we propose a revised, fluid model of Aurora-A activation in which the first step is a reducti
27        Ciliary phenotypes imply a failure of Aurora-A activation: Compatible with this idea, Pkd1(-/-
28                      We identify deregulated Aurora A activity as a mechanism contributing to the pri
29 s both INCENP and Aurora B activity (but not Aurora A activity) and is critical for Polo function at
30 quently, loss of CHK2 or PP6C-SAPS3 promotes Aurora-A activity associated with BRCA1 in mitosis.
31 hich the CHK2-BRCA1 axis restrains oncogenic Aurora-A activity during mitosis and identify BRCA1 itse
32 lation of BRCA1 leads to increased oncogenic Aurora-A activity, which acts as a mediator for abnormal
33 n be significantly rescued by drug-resistant Aurora A alone.
34  stabilization mechanism in which binding to Aurora-A alters how N-Myc interacts with SCF(FbxW7) to d
35              These findings reveal that both Aurora A and B contribute to kinetochore-microtubule att
36                 In addition, AR-42 decreased Aurora A and B expression.
37                                          The Aurora A and B kinases directly phosphorylate Lgl to pro
38 ted protein 1, residues 549-855 (SPICE1), as Aurora A and B kinases substrates in vitro.
39 ors that disrupts the native conformation of Aurora A and drives the degradation of MYCN protein acro
40 cilia in proliferating cells, independent of Aurora A and HDAC6.
41               ALADIN interacts with inactive Aurora A and is recruited to the spindle pole after Auro
42 rotein, such as small-molecule inhibitors of Aurora A and mTOR, are currently being evaluated in earl
43  protein was overexpressed concurrently with Aurora A and NF-kappaB signaling factors in patients wit
44                     Concurrent inhibition of Aurora A and PI3K signaling overcame PI3K inhibitor-indu
45                                              Aurora A and Plk1 are likely regulated downstream of sta
46  propose that Gravin-mediated recruitment of Aurora A and Plk1 to the mother (oldest) spindle pole co
47 tion of stathmin knockdown and inhibition of Aurora A and Plk1 was not additive and again delayed mit
48                  Chemical inhibition of both Aurora A and Plk1 was sufficient to delay mitotic entry
49 y a variety of cell cycle kinases, including Aurora A and Plk1, albeit at distinctive sites.
50 e, we monitor the phosphorylation of Bora by Aurora A and Plk1, analyzing the generated distinctive p
51              Here, we show that Cep192 binds Aurora A and Plk1, targets them to centrosomes in a peri
52 otein Gravin/AKAP12 and the mitotic kinases, Aurora A and Plk1, that is down regulated in human semin
53  control localization and activation of both Aurora A and Plk1.
54 tivity of CDC25 and its upstream activators, Aurora A and Plk1.
55                             We conclude that Aurora A and Plk4 are rate-limiting factors contributing
56 ially overlapping, nonredundant functions of Aurora A and Plk4 kinases contribute to initiate acentri
57 protein that activates the cell-cycle kinase Aurora A and regulates the mitotic spindle.
58 f a domain-swapped dimer of dephosphorylated Aurora A and TPX2(1-25).
59 further demonstrate that the mitotic kinases Aurora-A and -B phosphorylate KIBRA both in vitro and in
60 BRA is phosphorylated by the mitotic kinases Aurora-A and -B.
61  interaction between the catalytic domain of Aurora-A and a site flanking Myc Box I that also binds S
62 A depletion impaired the interaction between Aurora-A and PP1.
63  SMAD5, indicating a novel interplay between Aurora-A and SMAD5 signaling pathways in the development
64 the crystal structure of the complex between Aurora-A and this region of N-Myc to 1.72-A resolution.
65 t not BRAF, associates with Aurora kinase A (Aurora-A) and Polo-like kinase 1 (Plk1) at the centrosom
66 it acts independently of Galphai, the kinase Aurora A, and the phosphatase PP2A.
67 , and cyclin B1 and phosphorylation of PLK1, Aurora A, and TPX2 were rescued by inhibition of the ana
68 ch can individually increase the activity of Aurora-A, and the effect of both bound together is the e
69                           Elevated levels of Aurora-A are significantly associated with disease-free
70 ons because it highlights the mitotic kinase Aurora-A as a novel promising therapeutic target to sele
71 ogues p37/p47 resulted in an accumulation of Aurora A at centrosomes and a delay in centrosome separa
72 ation of active key mitotic kinases Plk1 and Aurora A at centrosomes and spindle poles.
73 ivity of cognate kinases (Erk1/2, Msk1/2 and Aurora A) at the Tnf-alpha locus.
74                              Most studies of Aurora A (AurA) describe it as a mitotic centrosomal kin
75 al delivery of Polo-like kinase 1 (Plk1) and Aurora A (AurA) inhibitors attenuates kinase activity, p
76                                              Aurora A (AurA) is a major mitotic protein kinase involv
77                           The mitotic kinase Aurora A (AurA) is regulated by a complex network of fac
78 ulatory allosteric pocket of the oncoprotein Aurora A (AurA) kinase, thereby offering the potential f
79  HEF1 scaffold and activating its associated Aurora-A (AurA), a kinase crucially required for primary
80                 The essential mitotic kinase Aurora A (AURKA) is controlled during cell cycle progres
81 nce-inducing inhibitor of the mitotic kinase Aurora A (AURKA) with an MDM2 antagonist activates p53 i
82            The Aurora kinases, which include Aurora A (AURKA), Aurora B (AURKB) and Aurora C (AURKC),
83 ed during cancer progression, interacts with Aurora-A (AURKA) kinase to control ciliary resorption, a
84 pment and homeostasis, we interbred a floxed Aurora-A (Aurora-A(fl)) mouse with the Cre-deleter strai
85 ch was associated with delayed activation of Aurora A, Aurora B, and cyclin-dependent kinase 1 (CDK1)
86 c M-phase, and identify a crucial APC/C-PP6c-Aurora A axis in the resumption of female meiosis.
87 s led to SAR156497, an exquisitely selective Aurora A, B, and C inhibitor with in vitro and in vivo e
88             Serine/threonine protein kinases Aurora A, B, and C play essential roles in cell mitosis
89 regulators LIM domain kinase 1, cofilin, and Aurora A/B/C.
90                      Unlike wild-type cells, Aurora-A(-/-) basal progenitors were delayed in forming
91                                    Moreover, Aurora A binding and phosphorylation of BRCA1 enhanced i
92                                 We show that Aurora A binds TPX2 and MLN8054 simultaneously and provi
93                            It was known that Aurora A/Bora activates Polo at centrosomes during late
94 hich acts as a T-loop phosphatase inhibiting Aurora-A bound to BRCA1.
95 e, our results suggest that unphosphorylated Aurora-A bound to the mitotic spindle by TPX2 is catalyt
96 important not only for the activity of human Aurora A but also for that of fission yeast MAPK-activat
97 ation process of the serine/threonine kinase Aurora-A by phosphorylation and by its protein partner,
98                                Activation of Aurora A can impinge on YAP activity through direct phos
99                 Furthermore, loss of TPX2 or Aurora A causes deprotection of stalled replication fork
100                              Loss of TPX2 or Aurora A compromises DNA end resection, BRCA1 and Rad51
101 tudies and biochemical assays, delineates an Aurora A conformation-specific effect on proteolytic deg
102 teric activation by TPX2 of dephosphorylated Aurora A could be at play in the spindle microtubules.
103  Furthermore, our data also illustrated that Aurora-A could not only induce mRNA and protein expressi
104                        Ectopic expression of Aurora-A decreases and depletion of Aurora-A enhances ta
105 vels of apoptosis or senescence, but because Aurora-A-deficient tumors accumulate polyploid cells wit
106 bitor, suggesting a centrosomal role for the Aurora A-dependent complex of clathrin, ch-TOG, and TACC
107                                              Aurora A-dependent NF-kappaB signaling portends poor pro
108                            Here we show that Aurora-A determines tamoxifen sensitivity by regulation
109                                              Aurora-A differs from Aurora-B/C at three positions in t
110   Using in vitro kinase assays, we show that Aurora A directly phosphorylates YY1 at serine 365 in th
111                         USP2a interacts with Aurora-A directly in vitro and in vivo.
112 A1 tumor suppressor axis restrains oncogenic Aurora-A during mitosis to ensure karyotype stability re
113 ssion of Aurora-A decreases and depletion of Aurora-A enhances tamoxifen sensitivity in ERalpha-posit
114                   Injection of ES cells into Aurora A epiblast knockout blastocysts reconstitutes emb
115  and polyploid keratinocytes were evident in Aurora-A(-/-) epidermis, indicating that a deficiency in
116 ferentiation marker keratin 1 was evident in Aurora-A(-/-) epidermis, there was a marked reduction in
117 nding to the AURKA promoter, which increased Aurora A expression in resistant GSCs.
118             We propose that a high degree of Aurora A expression may play a role in aggressive behavi
119 ntly positive correlation between Rap-1A and Aurora-A expression.
120 homeostasis, we interbred a floxed Aurora-A (Aurora-A(fl)) mouse with the Cre-deleter strain, K14.Cre
121                                              Aurora-A(fl/fl);Krt14.Cre (Aurora-A(-/-)) mice died shor
122              This paper thus describes a new Aurora A function that takes place after the metaphase-t
123 ew powerful tool to search for and study new Aurora A functions.
124                      These data suggest that Aurora-A has a pivotal role in tamoxifen resistance and
125          In this study, we identify the TPX2/Aurora A heterodimer, nominally considered a mitotic kin
126 pyrimidine 1 was identified as a potent hit (Aurora A IC(50) = 6.1 +/- 1.0 nM) from in-house screenin
127                                 Knockdown of Aurora A impaired cell growth, induced mitotic arrest an
128                         This inhibitor locks Aurora A in an inactive conformation and disrupts bindin
129                           The involvement of Aurora A in events after metaphase has only been suggest
130  and suggest therapeutic use from inhibiting Aurora A in head and neck cancers, which overexpress BMI
131 ics, and they uncover an unexpected role for Aurora A in late mitosis.
132  B-ring inhibited the autophosphorylation of Aurora A in MDA-MB-468 breast cancer cells.
133                              Inactivation of Aurora A in the epiblast or visceral endoderm layers of
134 ts uncover a novel mechanism that implicates Aurora A in the mitotic inactivation of transcription fa
135                     In contrast, mutation of Aurora A in the visceral endoderm, leads to posterioriza
136 I1/hSNF5 leads to aberrant overexpression of Aurora A in these tumors, which is required for their su
137 phosphorylate and potentiate the activity of Aurora A in vitro.
138 lized in neuroblastoma by the protein kinase Aurora-A in a manner that is sensitive to certain Aurora
139              Conditional genetic ablation of Aurora-A in adult tissues results in polyploid cells tha
140 cal tools to further explore the function of Aurora-A in cells.
141                       To address the role of Aurora-A in skin development and homeostasis, we interbr
142                        Thus, the deletion of Aurora-A in the developing epidermis alters centrosome f
143 sters on Hice1 that can be phosphorylated by Aurora-A in vitro.
144                                              Aurora-A, in turn, then phosphorylates BRCA1 itself, the
145 structure indicates that the conformation of Aurora-A induced by compounds such as alisertib and CD53
146 A and is recruited to the spindle pole after Aurora A inhibition.
147  Critically, these effects are reproduced by Aurora A inhibition.
148 verning the observed isoform selectivity for Aurora-A inhibition.
149 imized by structure-based design to a potent Aurora A inhibitor (IC50 = 2 nM) with very high kinome s
150  IBPR compounds as well as MLN8237, a proven Aurora A inhibitor, as chemical probes to investigate th
151 et in tamoxifen-resistant breast cancer, and Aurora-A inhibitor could be used as either an independen
152                                     Notably, Aurora-A inhibitor MLN8237, which is currently in clinic
153 so observed in glioma cells treated with the Aurora-A inhibitor TC-A2317 or anti-Aurora-A siRNA.
154  activity of Aurora-A, we show here that two Aurora-A inhibitors, MLN8054 and MLN8237, disrupt the Au
155                                 Furthermore, Aurora-A interacts with and phosphorylates ERalpha on se
156                 These results indicated that Aurora A is a direct downstream target of INI1/hSNF5-med
157                                              Aurora A is a mitotic kinase essential for cell prolifer
158                         Here, we report that Aurora A is essential for Thr9 phosphorylation of the TR
159 he as-AurA with 1-Na-PP1, we discovered that Aurora A is required for central spindle assembly in ana
160                                              Aurora-A is a kinase involved in the formation and matur
161                                 In addition, Aurora-A is a substrate for USP2a in vitro and in vivo.
162                             We conclude that Aurora-A is an accessible target that makes destabilizat
163 active and that the phosphorylation state of Aurora-A is an inaccurate surrogate for its activity.
164                                     However, Aurora-A is not required for KIBRA to associate with Lat
165                                        Thus, Aurora-A is required for tumor formation in vivo, and th
166 (27e), a potent inhibitor of Aurora kinases (Aurora-A K(d) = 7.5 nM, Aurora-B K(d) = 48 nM), FLT3 kin
167                                     Finally, Aurora-A(-/-) keratinocytes displayed centrosomal abnorm
168                                    Increased aurora A kinase (AAK) expression occurs in acute myeloid
169                                              Aurora A kinase (AAK) is overexpressed in aggressive lym
170                                              Aurora A kinase (AAK) is upregulated in highly prolifera
171                         Here, we report that Aurora A kinase (AAK) opposes the stabilizing effect of
172 We report here the design of the first human Aurora A kinase (as-AurA) engineered by chemical genetic
173     We established a conditional deletion of Aurora A kinase (AurA) in Cdk1 analogue-sensitive DT40 c
174                                              Aurora A kinase (AURKA) is overexpressed in 96% of human
175 y activates the mitotic programme, including Aurora A kinase (Aurka), in stratified epithelia, and en
176 -throughput drug screening revealed that the Aurora A kinase (Aurora A)/Polo-like kinase 1 (PLK1)/cyc
177                                   Inhibiting Aurora A kinase activity attenuated BMI1-induced tumor g
178         Inhibition of Cdk1 activity, but not Aurora A kinase activity, prevents the translation of Mo
179 er than simple nanomolar-level inhibition of Aurora A kinase activity.
180            In this study, we determined that Aurora A kinase acts as a positive regulator for YAP-med
181 ental Cell, Zhao et al. (2019) show that the Aurora A kinase AIR-1 is the long-sought cue that downre
182 over that C. elegans zygotes depleted of the Aurora A kinase AIR-1 or lacking centrosomes entirely us
183 eased expression of p53, reduced activity of aurora A kinase and a subsequent delay in the activation
184 rect ancestors of two colocalizing proteins, Aurora A kinase and its allosteric activator TPX2 (targe
185            Additionally, we demonstrate that Aurora A kinase associates with inner centromere protein
186  cells showed reduced activation of Plk1 and Aurora A kinase at spindle poles and an impaired localiz
187 le attachments are restored by inhibition of Aurora A kinase at spindle poles.
188  this study, x-ray crystal structures of the Aurora A kinase domain delineate redox-sensitive cystein
189 s residue promote autophosphorylation of the Aurora A kinase domain.
190                                 Knowledge of Aurora A kinase functions is limited to premetaphase eve
191 n but also shed new light on the function of Aurora A kinase in the reprogramming process.
192 enance, and destabilization of N-Myc through Aurora A kinase inhibition reduces tumor burden.
193 two MYCN-targeted small-molecule inhibitors, Aurora A kinase inhibitor alisertib (MLN8237) and mTOR i
194                         Alisertib is an oral Aurora A kinase inhibitor with preclinical activity in n
195 olleagues demonstrate unequivocally that the Aurora A kinase inhibitor, alisertib, specifically neutr
196       This was phenocopied by treatment with Aurora A kinase inhibitor, suggesting a centrosomal role
197 agement of neuroendocrine prostate cancer as Aurora A kinase inhibitors promoting N-Myc destabilizati
198 date the efficacy of novel therapies such as Aurora A kinase inhibitors.
199 copy, we have determined that phosphorylated Aurora A kinase is in dynamic equilibrium between a DFG-
200              Here we investigate the role of Aurora A kinase on AR-Vs in models of CRPC and show depl
201 oduce (18)O label into bacterially expressed Aurora A kinase phosphorylation sites and resulted in th
202 of p38, inositol trisphosphate 3-kinase, and Aurora A kinase potently enhance iPSC generation, and iP
203 ypertension drug felodipine to the oncogenic Aurora A kinase protein via hydrogen bonding interaction
204           In this study, we demonstrate that Aurora A kinase regulates kinetochore-microtubule dynami
205 tor YY1 as a novel mitotic substrate for the Aurora A kinase, a key regulator of critical mitotic eve
206 ic spindle formation and known substrates of Aurora A kinase, resulting in spindle assembly and cytok
207                                 We show that Aurora A kinase, which functions in centrosome activity
208          One of these mitotic controllers is Aurora A kinase, which is itself highly regulated.
209  Regulation of MCAK function is dependent on Aurora A kinase, which is regionally enhanced by signali
210 le in two similar hydrophobic pockets in the Aurora A kinase.
211 dipine as a specific inhibitor for oncogenic Aurora A kinase.
212 ation and TPX2-mediated activation) in human Aurora A kinase.
213              The catalytic activity of human AURORA-A kinase (AURKA) regulates mitotic progression, a
214                              The centrosomal Aurora-A kinase (AURKA) regulates mitotic progression, a
215                           Moreover, aberrant Aurora-A kinase activity induced phosphorylation and nuc
216  pharmacological and molecular inhibition of Aurora-A kinase activity restored a CD24(+) epithelial p
217 oss, which also requires the activity of the Aurora-A kinase AIR-1.
218 pindle assembly factor TPX2, which activates Aurora-A kinase and stimulates local microtubule nucleat
219  findings, our data clearly demonstrate that Aurora-A kinase does not regulate TACC3-chTOG complex fo
220 s show for the first time the causal role of Aurora-A kinase in the activation of EMT pathway respons
221                     Here, we report that the Aurora-A kinase inhibitor alisertib exhibits potent effi
222  treatment of Pkd1(-/-) mice with a clinical Aurora-A kinase inhibitor exacerbated cystogenesis.
223 amics is spatially controlled through a Rac1-Aurora-A kinase pathway that locally inhibits the MT dep
224                          Here, we found that Aurora-A kinase, a major mitotic kinase, specifically bi
225               N-Myc forms a complex with the Aurora-A kinase, which protects N-Myc from proteasomal d
226 n carcinoma cells, 28c and 40f inhibited the Aurora-A L215R and R220K mutants with IC50 values simila
227              In agreement, overexpression of Aurora-A leads to increased H3 T118ph levels, causing co
228                                 We show that Aurora A levels increase in advanced disease and AURKA i
229 to its activator protein TPX2, which impairs Aurora A localization at the mitotic spindle and induces
230                                              Aurora A localization to the centrosome required MTs, wh
231 s embryos, centrosomes recruited more AIR-1 (Aurora A), matured precociously, and alignment of the mi
232 edox modulation of the conserved Cys(290) of Aurora A may be an underappreciated regulatory mechanism
233                                 Thus, a Rac1-Aurora A-MCAK signaling pathway mediates EC polarization
234                                 We show that Aurora-A mediated H3 T118ph occurs at pericentromeres an
235                  Two new studies describe an Aurora A-mediated error correction mechanism based on th
236               Altogether, our findings of an Aurora A-mediated interaction of Merlin with alpha-tubul
237              Drug-resistant Plk4 can enhance Aurora A-mediated rescue, and, accordingly, Plk4 can pho
238                   Aurora-A(fl/fl);Krt14.Cre (Aurora-A(-/-)) mice died shortly after birth.
239 ng induces stabilization and accumulation of Aurora-A mitotic kinase that ultimately drives the trans
240   Taken together, these results suggest that Aurora-A modulates the microtubule binding activity of H
241 notype can be rescued by inhibitor-resistant Aurora A mutants.
242 cogenic networks including HIPPO-YAP/TAZ and AURORA-A/MYCN pathways.
243 inhibitors, MLN8054 and MLN8237, disrupt the Aurora-A/N-Myc complex and promote degradation of N-Myc
244                            Disruption of the Aurora-A/N-Myc complex inhibits N-Myc-dependent transcri
245 -deficient cells, as were phosphorylation of Aurora A on threonine 288, phosphorylation of Polo-like
246 lective inhibitors, such as compound 28c, of Aurora-A over Aurora-B.
247                  Elevated cytoplasmic p73 in Aurora-A overexpressing primary human tumors corroborate
248        These effects were phenocopied by the Aurora A phosphomimetic mutation, S719E.
249                                              Aurora-A phosphorylated p73 also facilitates inactivatio
250                        A dileucine motif and Aurora A-phosphorylated serine 558 on TACC3 bound to the
251     By analyzing these mutants, we show that Aurora A phosphorylates the condensin I-dependent pool o
252                               We report that Aurora-A phosphorylation of p73 at serine235 abrogates i
253               In all, our data suggests that Aurora A plays a pivotal role in regulation of AR-V7 exp
254                            We find that TPX2/Aurora A plays a previously unrecognized role in DNA dam
255   We further found that the Cep192-dependent Aurora A-Plk1 activity is essential for kinesin-5-mediat
256          Manipulating elements of the Gravin-Aurora A-Plk1 axis prompts mitotic delay and prevents ap
257 screening revealed that the Aurora A kinase (Aurora A)/Polo-like kinase 1 (PLK1)/cyclin-dependent kin
258 late the activation/deactivation of Plk1 and Aurora A, possibly by linking them to mTOR signaling in
259            Specifically, YAP associates with Aurora A predominantly in the nucleus.
260                   Therapeutic elimination of Aurora-A prevents the progression of skin and mammary gl
261                        Thus, CRM1, BARD1 and Aurora A promote the targeting and function of BRCA1 at
262 ay indicated that INI1/hSNF5 associates with Aurora A promoter in RT and normal cells but not in non-
263 ) epidermis, indicating that a deficiency in Aurora-A promotes aberrant mitosis, mitotic slippage, an
264                             Aurora kinase-A (Aurora-A) promotes timely entry into mitosis, centrosome
265         Embryos with an epiblast ablation of Aurora A properly establish the anteroposterior axis but
266 Taken together, our results suggest that the Aurora-A/Rap-1A pathway is associated with survival, tum
267                    Importantly, knockdown of Aurora A reconfigures splicing of AR pre-mRNA to discrim
268 R-Vs in models of CRPC and show depletion of Aurora A reduces AR-V target gene expression.
269 itosis, ATR localizes to centromeres through Aurora A-regulated association with centromere protein F
270 is and identify BRCA1 itself as a target for Aurora-A relevant for CIN.
271                                        Thus, Aurora-A represents a prognostic marker in ERalpha-posit
272                         In mice, ablation of Aurora A results in mitotic arrest and pre-implantation
273                                Inhibition of Aurora-A results in mitotic defects, and this kinase is
274 principle for imidazo[4,5-b]pyridine-derived Aurora-A-selective inhibitors.
275 a-A in a manner that is sensitive to certain Aurora-A-selective inhibitors.
276     Moreover, aberrant expression of YAP and Aurora A signaling is highly correlated with triple-nega
277 with the Aurora-A inhibitor TC-A2317 or anti-Aurora-A siRNA.
278 CC3-chTOG complex formation, indicating that Aurora-A solely functions as a recruitment factor for th
279                              Without ALADIN, Aurora A spreads from centrosomes onto spindle microtubu
280  of mitotic genes including Aurora Kinase A (Aurora A, STK6).
281  target site in the Hec1 tail, as a critical Aurora A substrate for this regulation.
282 k1 promotes phosphorylation of human Plk1 by Aurora A, suggesting that this mechanism is conserved in
283                                 However, the Aurora-A T217E mutant was significantly less sensitive t
284 s upstream activators polo-like kinase 1 and Aurora-A, targeted Hsp72 to the poles of cells with ampl
285 r 31, 2015, at Children's Hospital Colorado, Aurora, a tertiary care children's hospital.
286 -position led to highly potent inhibitors of Aurora A that bind in a DFG-out conformation.
287 t an indirect regulatory mechanism involving Aurora A that may account for Gwl-dependent regulation o
288 ur results suggest that Wdr62 interacts with Aurora A to control mitotic progression, and loss of the
289 62 associates and genetically interacts with Aurora A to regulate spindle formation, mitotic progress
290      Here, we found that INI1/SNF5 represses Aurora A transcription in a cell-type-specific manner.
291 patches that may aid in distinguishing human Aurora A versus human Aurora B kinase in vivo.
292 the catalytic activity of the Ser/Thr kinase Aurora A was inhibited by the oxidation of a conserved c
293                                We found that Aurora A was required to mediate mitosis-driven GR phosp
294                                     Elevated Aurora-A was significantly associated with the recurrenc
295 c does not require the catalytic activity of Aurora-A, we show here that two Aurora-A inhibitors, MLN
296 1-activated kinase and its downstream kinase Aurora A, which are critical regulators of centrosome ma
297 s through upregulation of the mitotic kinase Aurora A, which is encoded by the AURKA gene.
298 uppressor 2 (Lats2) on Ser(83) by activating Aurora-A, which controls Lats2 centrosome localization.
299 to inhibition by 28c and 40f compared to the Aurora-A wild type, suggesting that the T217 residue pla
300 th IC50 values similar to those seen for the Aurora-A wild type.

 
Page Top